Photograph: L-R: Dr Michael Gantier, Stuart Emmerson, Dr Nick Boyd and Dr Shivani Pasricha
Researchers and students have pitched their innovative ‘Big Ideas’ tackling health conditions ranging from tackling Legionnaires disease to improving exercise science to a panel of research and commercialisation experts.
It was all part of the Next Big Idea […]
A student development evening was held on 13 August 2018 at Monash University Clayton where Professor Graham Jenkin a represented Cartherics Pty Ltd. More information regarding our PhD projects is available on our Opportunities page.
What open days are for ……
Our organising committee has been working relentlessly on this inaugural world conference having now assembled an excellent program of 40+ national and international opinion leaders. This conference is indeed something out of the ordinary.
Immunotherapy is on the cusp of revolutionising cancer treatment with some in the field even considering the potential of cure. With […]
Cartherics has been advised by the Hon Craig Laundy MP (Assistant Minister for Industry, Innovation and Science) that its application “Allogeneic Stem Cell Cancer Immunotherapies” in the 4th Cooperative Research Centres (CRC) Project Funding round has been successful.
Cartherics’ application was one of just 15 successful applications out of a total of 70 received in the 4th […]
Professor Jacques Miller a member of Cartherics’ Scientific Advisory Board wins “The Japan Prize Foundation says Walter and Eliza Hall Institute’s Prof Jacques Miller and Emory’s Prof Max Cooper have won the Japan Prize for Medical and Medicinal Science. A spokesperson for the Foundation told Biotech Daily that Prof Miller and Dr Cooper would share the […]
29 May 2018, Hudson Institute of Medical Research
‘Off-the-shelf’ immunotherapies to fight aggressive forms of cancer, including relapsed ovarian and gastric cancers, are being developed in Clayton, Melbourne, thanks to almost $3 million in Federal Government funding awarded to lead participant Cartherics Pty Ltd.
‘Off the shelf cancer hope as rare cell becomes tumour buster’